Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy

BACKGROUND: Vorapaxar is indicated with standard antiplatelet therapy (APT) in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). OBJECTIVES: To evaluate the comparative effects of vorapaxar on platelet-fibrin clot characteristics (PFCC), coagulation, inflamm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thromb Haemost
Main Authors: Bliden, Kevin, Chaudhary, Rahul, Kuliopulos, Athan, Tran, Henry, Taheri, Hamid, Tehrani, Behnam, Rosenblatt, Arnold, Navarese, Eliano, Tantry, Udaya S., Gurbel, Paul A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6940524/
https://ncbi.nlm.nih.gov/pubmed/31444884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14616
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados